Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.47 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.47 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12347458 | 0.83 | ALDH1A1 (0.41) | TDP1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL10272281 | 0.80 | POLB (0.38) | TDP1TSHRALDH1A1MAPTMEN1 | |
| SCHEMBL30598677 | 0.79 | ALDH1A1 (0.40) | TDP1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL31481286 | 0.79 | ALDH1A1 (0.40) | TDP1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL24557865 | 0.79 | ALDH1A1 (0.40) | TDP1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL2711056 | 0.77 | TSHR (0.41) | TDP1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL113455 | 0.76 | MAPK1 (0.44) | TSHRALDH1A1MAPK1AHRCHUK | |
| SCHEMBL29445407 | 0.76 | MAPK1 (0.44) | TSHRALDH1A1MAPK1AHRCHUK | |
| SCHEMBL17964135 | 0.75 | HTT (0.43) | TDP1TSHRCYP3A4ALDH1A1HPGD | |
| SCHEMBL16096096 | 0.74 | PARP1 (0.45) | TDP1TSHRCYP3A4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12275719-B2 | Small molecule inhibitors of galectin-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-15 | — | — | US | disclosed |
| EP-3947407-B1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023247593-A1 | PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247593-A1 | PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| CN-117043156-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-4267570-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2023-11-01 | — | — | EP | disclosed |
| CN-116710447-A | Novel galectin inhibitors of galectins | 格莱克特生物技术公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023118267-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022144274-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022136365-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022136365-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-06-30 | — | — | WO | disclosed |
| US-20220185800-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220185800-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3947407-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113727988-A | Small molecule inhibitors of galectin-3 | 百时美施贵宝公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2020198266-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2019067702-A9 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019067702-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275719-B2 | Small molecule inhibitors of galectin-3 | LGALS3, LGALS1, LGALS3BP | TDP1 1921/4885TSHR 1382/4885CYP3A4 4137/4885 |
| US-20220185800-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | TDP1 1921/4885TSHR 1382/4885CYP3A4 4137/4885 |
| US-20210147408-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | TDP1 1539/4885TSHR 1412/4885CYP3A4 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.